Alpine Immune Sciences Reports First Quarter 2024 Financial Results
Alpine Immune Sciences Inc ALPN
News
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CRC, HRT, ALPN, MCBC
ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AIRC, ALPN, WIRE
INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Alpine Immune Sciences, Inc. - ALPN
ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN
Kuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to Contact Law Firm
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, ELYM, MODN
Shareholder Alert: Ademi LLP investigates whether Alpine Immune Sciences, Inc. has obtained a Fair Price in its transaction with Vertex
ALPN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alpine Immune Sciences, Inc. Is Fair to Shareholders
Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition
Alpine Immune Sciences Shares Rally After Vertex Agrees to Acquire Co.
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion — Update
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion
Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024
Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024